Assessment of the risk of coronary heart disease in women with systemic lupus erythematosus;Avaliação do risco coronariano em mulheres com lúpus eritematoso sistêmico

Revista Brasileira de Reumatologia

Volumn 49, Issue 6, 2009, Pages 658-669

  Cadaval, Ricardo A M ^a   Martinez, José Eduardo ^a   Mazzolin, Milene A ^a   Barros, Renata G T ^a   De Almeida, Fernando Antonio ^a  

^a PONTIFÍCIA UNIVERSIDADE CATÓLICA DE SÃO PAULO   (Brazil)

Author keywords

Cardiovascular risk; Framingham risk score; Systemic lupus erythematosus

Indexed keywords

TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PATIENT ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 75149169764     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042009000600003     Document Type: Article

References (42)

1. Merrel M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J. Chronic Dis 1955; 1:12-32.
2. Pistiner M, Wallace DJ, Nessim S. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin. Arthritis Rheum 1991; 21:55-64.
3. Cervera R, Khamashta MA, Font J. Morbility and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestation in a cohort of 1000 patients. Medicine 2003; 82:299-308.
4. Urowitz MB, Bookman AAM, Koehller BE. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60:221-5.
5. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Reumathol 1995; 22:1259-64.
6. Rubin LA, Urowitz MB, Gladman DD. Mortality is systemic lupus erythematosus: bimodal pattern revised. Q J Med 1985; 55:87-98.
7. Moss KE, Ioannou Y, Sultan SM. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002; 61:409-13.
8. Jonsson J, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989; 68:141-50.
9. Futrell N, Millikan C. Frequency, etiology and prevention of stroke in patients with systemic lupus erythematosus. Stroke 1989; 20:583-91.
10. Kitagawa Y, Gotoh F, Koto A, Okayasu H. Stroke in systemic lupus erythematosus. Stroke 1990; 21:1533-9.
11. Urowitz MB, Abu-Shakra M, Gladman DD, Gough J, Farewell VT. Improved survival in SLE. J. Rheumatol 1997; 24:1061-5.
12. Roldan CA, Shively BK, Lau CC, Gurule FT, Smith EA, Crawford MH. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol 1992; 20:1127.
13. Roman MJ, Shanker BA, Davis A. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399-406.
14. Doria A, Shoenfeld Y, Wu R. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62:1071-7.
15. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham Risk Factors to Fully Account for Accelerated Atherosclerosis in Systemic Lupus Erythematosus. Arthritis & Rheumatism 2001; 44:2331-7.
16. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in Johns Hopkins Lupus Cohort: prevalence, recognition by patients and preventive practices. Medicine (Baltimore) 1992; 71:291-302.
17. Manzi S, Meilahn EM, Rairie JE. Age specific incidence rates of myocardial Infarction and angina in women with systemic lupus erythematosus: comparison with Framingham study. Am J Epidemiol 1997; 145:408-15.
18. Wilson PW, D'Agostinho RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-59.
19. Hochberg, MC. Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
20. Gladmann DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI). J Rheumatol 2002; 29:288-9.
21. Chung, CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15:562-9.
22. Avina-Zubieta JA, Galindo-Rodríguez G, Newman S, Suarez-Almozor ME, Russell AS. Long-term effectiveness of antimalarial drugs in rheumatic disease. Ann Rheum Dis 1998; 57:582-7.
23. Sachet JC, Borba EF, Bonfá E et al. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus. 2007; 16:273-8.
24. Borba EF, Bonfá E. Long-term beneficial effect of chloroquine diphosphate on lipoprofile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28:780-5.
25. Petri M, Perez-Gutthann S, Spencer D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93:513-19.
26. Chung CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15:562-9.
27. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-26.
28. Hansson GK, Libby O, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91:281-91.
29. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135:169-75.
30. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum 2003; 48:3159-67.
31. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-43.
32. Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004; 112:169-74.
33. Ho CY, Wong CK, Li EK, Tam LS, Lam CW. Elevated plasma concentration of nitric oxide, solute thrombomodulin and solute vascular cell adhesion molecule-1 with systemic lupus erythematosus. Rheumatology 2003; 42:117-122.
34. Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzamn phenomenon revised. Arthritis Rheum 1994; 37:376-83.
35. Formiga F, Meco JF, Pinto X et al. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001; 10:359-63.
36. Ettinger WH, Goldberg AP, Appelbaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987; 83:503-8.
37. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21:1264-7.
38. Kashef S, Ghaedian MM, Rajaee A, Ghaedian A. Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies. Rheumatol Int 2007; 27:235-41.
39. Borba EF, Bonfá E, Vinagre CG, Ramires JA, Maranhão RC. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000; 43:1033-40.
40. Borba EF, Bonfá E. Dyslipoproteinemia in systemic lupus erythematosus: influence of disease, activity and anticardiolipin antibodies. Lupus 1997; 6:533-9.
41. Leeuw K, Freire B, Smit AJ et al. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 2006; 15:675-82.
42. Delnocencio J, Lovell DJ. Cardiac function in systemic lupus erythematosus. J. Rheumathol 1994; 21:2147-56.